Search for: "Nicholson Price"
Results 61 - 80
of 160
Sort by Relevance
|
Sort by Date
10 Sep 2020, 6:23 pm
By Nicholson Price, Rachel Sachs, Jacob S. [read post]
Why is HHS blocking FDA from regulating some diagnostics, and how will this affect COVID-19 testing?
25 Aug 2020, 4:50 pm
By Lisa Larrimore Ouellette, Nicholson Price, Rachel Sachs, and Jacob S. [read post]
19 Aug 2020, 10:58 am
Sherkow, Lisa Larrimore Ouellette, Nicholson Price, and Rachel SachsModerna, Inc., a Cambridge, MA-based biotech company, is a leading contender in the race to develop a SARS-CoV-2 vaccine. [read post]
5 Aug 2020, 11:43 am
By Nicholson Price, Rachel Sachs, Jacob S. [read post]
30 Jul 2020, 3:39 pm
By Lisa Larrimore Ouellette, Nicholson Price, Rachel Sachs, and Jacob S. [read post]
22 Jul 2020, 12:12 pm
Sherkow, Lisa Larrimore Ouellette, Nicholson Price, and Rachel SachsOver 120 years ago, a milk wagon horse named Jim was the United States’ most potent weapon against a raging diphtheria epidemic. [read post]
10 Jul 2020, 8:59 am
Sherkow, Lisa Larrimore Ouellette, and Nicholson PricePolicymakers are expectantly awaiting the development of a COVID-19 vaccine, which they view as critical to future management of the pandemic. [read post]
2 Jul 2020, 10:15 am
By Nicholson Price, Rachel Sachs, Jacob S. [read post]
24 Jun 2020, 5:36 pm
By Lisa Larrimore Ouellette, Nicholson Price, Rachel Sachs, and Jacob S. [read post]
22 Jun 2020, 11:45 am
Our speakers are: June 25: Jacob Sherkow on COVID-19 Related Drug Shortages and Innovation Policy July 2: Nicholson Price on Public Funding and COVID-19 Innovation July 9: Sapna Kumar on Patents, Pharma, and the Pandemic July 16: Rachel E. [read post]
18 Jun 2020, 1:23 pm
Sherkow, Lisa Larrimore Ouellette, Nicholson Price, and Rachel SachsIn the United States, one of the most important factors in receiving COVID-19 testing or treatment is access to insurance. [read post]
2 Jun 2020, 10:31 pm
By Nicholson Price, Rachel Sachs, Jacob S. [read post]
27 May 2020, 12:00 pm
By Lisa Larrimore Ouellette, Nicholson Price, Rachel Sachs, and Jacob S. [read post]
20 May 2020, 1:58 pm
Guest Post by Colleen V. [read post]
19 May 2020, 3:30 pm
Sherkow, Lisa Larrimore Ouellette, Nicholson Price, and Rachel SachsLast week, we focused on incentives for developing clinical evidence supporting the use of remdesivir for COVID-19 and analyzed the FDA’s grant of an emergency use authorization (EUA) for the drug. [read post]
How is regulatory policy influencing the development and marketing of antibody testing for COVID-19?
4 May 2020, 12:56 pm
By Nicholson Price, Rachel Sachs, Jacob Sherkow, and Lisa Larrimore OuelletteOver the last few weeks, dozens of companies have begun marketing tests intended to determine whether someone has antibodies directed to SARS-CoV-2, the virus that causes COVID-19. [read post]
29 Apr 2020, 9:33 pm
Image by Mari Nicholson from Pixabay [read post]
27 Apr 2020, 1:27 pm
By Lisa Larrimore Ouellette, Nicholson Price, Rachel Sachs, and Jacob SherkowHealth systems worldwide are facing shortages of crucial medical supplies, including personal protective equipment (PPE), diagnostic testing components including kits and nasal swabs, and even ventilators or ventilator parts. [read post]
21 Apr 2020, 2:09 pm
By Lisa Larrimore Ouellette, Nicholson Price, Rachel Sachs, and Jacob SherkowOur recent posts have highlighted shortages in three COVID-19-related knowledge goods: testing, drugs (such as those needed to put patients on ventilators), and clinical trial information about effective treatments. [read post]
16 Apr 2020, 3:30 am
Nicholson Price II, The Costs of Novelty, __ Colum. [read post]
